Tyrosine kinase 2 (TYK2) Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2034

Key Highlights:

• Tyrosine Kinase 2 (TYK2) inhibitors are effective treatments for psoriasis, psoriatic arthritis, hidradenitis suppurativa, Inflammatory Bowel Disease (IBD), dermatomyositis, Crohn's disease, Systemic Lupus Erythematosus (SLE), ulcerative colitis, and other indications.
• The only TYK2 inhibitor approved to date is Bristol-Myers Squibb's SOTYKTU (deucravacitinib), which received FDA approval for the treatment of moderate-to-severe plaque psoriasis in September 2022.
• Market size of SOTYKTU was USD 190 million in the US, in 2024, with a 32% year-over-year increase.
• Several companies, including Priovant Therapeutics (brepocitinib), Alumis (ESK-001), Galapagos (GLPG366), Takeda (zasocitinib), and others are engaged in the development of TYK2 inhibitors.
• In March 2025, Alumis and Kaken Pharmaceutical entered into a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases.
• In December 2024, Bristol Myers Squibb announced results from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase III trials, which assessed the efficacy and safety of SOTYKTU (deucravacitinib) in adults with active psoriatic arthritis.
• Overall, this is an exciting class that holds great potential for the development of treatment for autoimmune disorders and other indications. The maturation of current studies over the next few years will lead to a better understanding of TYK2 inhibitors and define their role in the therapy of autoimmune indications.

DelveInsight's "Tyrosine kinase 2 (TYK2) Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the TYK2 inhibitors, historical and competitive landscape as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The TYK2 inhibitors' market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM TYK2 inhibitors' market size from 2020 to 2034. The report also covers current TYK2 inhibitors' treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Tyrosine kinase 2 (TYK2) Inhibitors Understanding and Treatment Algorithm

Tyrosine kinase 2 (TYK2) Inhibitors Overview

TYK2 is a member of the Janus kinase (JAK) family. It is an important mediator in pro-inflammatory signaling, implicated in both innate and adaptive immune systems. Activation of TYK2 is believed to be integral to cellular processes that contribute to the development and progression of autoimmune disorders. Selective targeting of TYK2 may reduce the number of adverse events as compared to non-selective JAK inhibitors. TYK2 inhibitors are a class of drugs that block the function of TYK2, an enzyme involved in the body's immune system and associated with inflammation. By inhibiting TYK2, these inhibitors aim to reduce inflammation and its associated symptoms. TYK2 inhibitors are being explored for the treatment of various autoimmune diseases, including psoriasis, psoriatic arthritis, IBD and others.

Tyrosine Kinase 2 (TYK2) Inhibitors Market Overview

In recent years, there has been a growing interest in the exploration of TYK2 inhibitors for a variety of inflammatory disorders, encompassing psoriasis, psoriatic arthritis, hidradenitis suppurativa, IBD, dermatomyositis, SLE, Crohn's disease, and other indications.

Tyrosine Kinase 2 (TYK2) Inhibitors Epidemiology

The epidemiology chapter of TYK2 inhibitors in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for TYK2 inhibitors, total eligible patient pool in selected indications for TYK2 inhibitors, and total treated cases in selected indications for TYK2 inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The diagnosed prevalent cases of SLE in 7MM in 2024 were nearly 1,053,700.
• In the US, plaque psoriasis is estimated to manifest in 2-3% of the adult population, with moderate-to-severe plaque psoriasis developing in approximately 20% of patients with plaque psoriasis.
• Among the EU4 and the UK, Germany accounted for the highest number of cases of hidradenitis suppurativa, followed by the UK and the lowest number of cases in Spain in 2024.
• Japan accounted for nearly 74,150 diagnosed prevalent cases of Crohn's disease in 2024.

Tyrosine Kinase 2 (TYK2) Inhibitors Drug Chapters

The drug chapter segment of the TYK2 inhibitors report encloses a detailed analysis of approved TYK2 inhibitors, late-stage (Phase III and Phase II) TYK2 inhibitors. It also helps understand the clinical trial details of TYK2 inhibitors, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Tyrosine Kinase 2 (TYK2) Inhibitors

SOTYKTU (deucravacitinib): Bristol-Myers Squibb

SOTYKTU is a selective, allosteric inhibitor of TYK2. TYK2 is a member of the JAK family. SOTYKTU binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. Janus kinases function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways and also pairs with JAK2 to transmit signals as shown in cell-based assays. The precise mechanism linking inhibition of TYK2 enzyme to therapeutic effectiveness in the treatment of adults with moderate-to-severe plaque psoriasis is not currently known.

The therapy is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Emerging Tyrosine Kinase 2 (TYK2) Inhibitors

ESK-001: Alumis

ESK-001 is a TYK2 inhibitor that reduces signaling through several cytokine receptors including receptors for interleukin (IL)-23, and type 1 interferon. ESK-001 has the potential to reduce SLE disease activity by interfering with pro-inflammatory pathways known to be involved in the pathogenesis of SLE. It is being evaluated in Phase II.

Brepocitinib: Priovant Therapeutics

Priovant's lead molecule is brepocitinib, an oral once-daily dual inhibitor of TYK2 and JAK1. By selectively inhibiting both TYK2 and JAK1, brepocitinib is optimized to suppress signaling of a wide range of TYK2- and JAK1-dependent cytokines linked to autoimmunity, including type I and type II interferon, IL-6, IL-12, and IL-23.

Priovant is developing brepocitinib across multiple severe autoimmune diseases. The company is currently running the VALOR Study, a fully enrolled single registrational Phase III trial evaluating brepocitinib in dermatomyositis patients, with top-line results expected in 2025. The company also recently initiated the Phase III CLARITY Study of brepocitinib in Non-infectious Uveitis (NIU), following successful results from the Phase II NEPTUNE Study. Priovant plans to initiate a Phase II study of brepocitinib in cutaneous sarcoidosis in 2025.

Tyrosine Kinase 2 (TYK2) Inhibitors Market Outlook

The global TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical pipeline activity, and expanding regulatory approvals.

Several key players, including Takeda, Alumis, Priovant Therapeutics, and others, are involved in developing drugs for TYK2 inhibitors such as Crohn's disease, psoriasis, dermatomyositis, and others, respectively. Overall, this is an exciting new class with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of TYK2 inhibitors and define their role in autoimmune indications.

Tyrosine Kinase 2 (TYK2) Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging TYK2 inhibitors expected to be launched in the market during 2025-2034.

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for TYK2 inhibitors market growth over the forecast period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for TYK2 inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on TYK2 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Washington University and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or TYK2 inhibitors' market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key Updates on Tyrosine Kinase 2 (TYK2) Inhibitors

• In March 2025, Alumis announced positive 52-week data from the open-label extension of its Phase II STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque psoriasis. The results were presented during a late-breaking session at the 2025 American Academy of Dermatology Association (AAD) Annual Meeting 2025.
• In December 2024, Neuron23 announced the commencement of dosing in a Phase I clinical trial of NEU-111 in healthy volunteers.

The abstract list is not exhaustive, will be provided in the final report

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the TYK2 inhibitors, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the TYK2 inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM TYK2 inhibitors market.

Tyrosine Kinase 2 (TYK2) Inhibitors Report Insights

• TYK2 Inhibitors Targeted Patient Pool
• Therapeutic Approaches
• TYK2 Inhibitors Pipeline Analysis
• TYK2 Inhibitors Market Size and Trends
• Existing and future Market Opportunities

Tyrosine Kinase 2 (TYK2) Inhibitors Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Tyrosine Kinase 2 (TYK2) Inhibitors Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What was the total market size of TYK2 inhibitors, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for TYK2 inhibitors?
• What are the pricing variations among different geographies for approved therapies?
• How has the reimbursement landscape for TYK2 inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with TYK2 inhibitors? What will be the growth opportunities across the 7MM for the patient population of TYK2 inhibitors?
• What are the key factors hampering the growth of the market for TYK2 inhibitors?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for TYK2 inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the TYK2 inhibitors market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.